Morgan Stanley analyst Michael Cyprys maintains Nasdaq (NASDAQ:NDAQ) with a Overweight and raises the price target from $250 to $252.
Second Sight Medical Gains FCC Approval For ‘Argus R 2s Glasses A2S01’
https://fccid.io/SMRA2S01
Morgan Stanley Maintains Overweight on Nasdaq, Raises Price Target to $252
Morgan Stanley analyst Michael Cyprys maintains Nasdaq (NASDAQ:NDAQ) with a Overweight and raises the price target from $250 to $252.
Related Posts
Dolby Laboratories Names Robert Park As CFO
Dolby Laboratories, Inc. (NYSE:DLB), a leader in immersive entertainment experiences, today announced the appointment of Robert Park, a global finance leader with a track record of guiding companies through growth, as
China’s Major State-owned Banks Seen Selling Dollars in Onshore Spot Market to Stabilize Yuan Exchange Rate
-Reuters
https://www.reuters.com/article/china-yuan/chinese-state-banks-dollar-selling-meant-to-prevent-the-spot-price-from-weakening-past-7-25-yuan-sources-idUSP8N2ZZ02E
Delta Air Lines Stock Falls After Q3 Results, Expects Fuel Pices To Hurt Q4 Profit
Delta Air Lines, Inc. (NYSE:DAL) reported a third-quarter FY21 adjusted operating revenue decline of 34% from 3Q19 to…